Suicide Prevention Intervention for Schizophrenia-Spectrum Disorders

Schizophrenia Clinical Trial

— CLASP-S  

Official title:

Post-Hospital Suicide Prevention Intervention for Patients With Schizophrenia-Spectrum Disorders

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04221269
• Other study ID #: 1908-001
• Status: Completed
• Phase: N/A
• Start date: December 1, 2020
• Est. completion date: June 1, 2023

Study information

• Verified date: July 2023
• Source: Butler Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The current project is a pilot randomized controlled trial to test the Coping Long-term with Active Suicide Program for schizophrenia-spectrum disorders (CLASP-S) for patients following a psychiatric hospitalization. Participants will be assigned to enhanced treatment as usual (ETAU) alone vs CLASP-S plus ETAU. Participants complete assessments at baseline during their psychiatric hospitalization and at 3 months (mid-treatment) and 6 months (post-treatment) following discharge. The primary aim is to assess the feasibility and acceptability of CLASP-S. The secondary aim is to estimate the effects of CLASP-S on reducing suicidal thoughts and behaviors relative to ETAU.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: June 1, 2023
• Est. primary completion date: June 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• suicidal thoughts or behaviors prior to hospital admission

• diagnosis of a schizophrenia-spectrum disorder

• receiving pharmacotherapy

• 18 years or older

• speaks/reads English

Exclusion Criteria:

• psychosis due to substance use or medical condition

• lack of phone access

• discharge to long-term facility

Related Conditions & MeSH terms

• Schizophrenia
• Suicide
• Suicide Prevention

Intervention

Behavioral:
• Enhanced Treatment as Usual
Routine community care plus assessment feedback reports to clinicians.
• Coping Long-term with Active Suicide Program for Schizophrenia
Adjunctive psychosocial intervention for suicide prevention involving in person, family, and phone sessions.

Locations

Country	Name	City	State
United States	Butler Hospital	Providence	Rhode Island

Sponsors (2)

Lead Sponsor	Collaborator
Butler Hospital	American Foundation for Suicide Prevention

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Client Satisfaction Questionnaire	The Client Satisfaction Questionnaire is a self-report measure of patient satisfaction with treatment. The total score (sum of items) will be used and ranges from 8 to 32 with increased scores indicating greater satisfaction with treatment.	6 months
Secondary	Columbia Suicide Severity Rating Scale	The Columbia Suicide Severity Rating Scale is an interviewer-rated measure of suicidal thoughts and behaviors. The total score (sum of items) will be used and ranges from 2 to 25 with higher scores indicating higher suicidal thoughts and behaviors.	6 months